Skip to content

Neurohumoral Mechanism of Deferent Frequency Transcutaneous Electrical Acupoint Stimulation(TEAS)

Neurohumor Mechanism of Deferent Frequency Transcutaneous Electrical Acupoint Stimulation(TEAS): A Prospective, Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02611388
Enrollment
81
Registered
2015-11-20
Start date
2015-12-31
Completion date
2016-06-30
Last updated
2015-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension

Brief summary

The purpose of this study is to explore the neurohumoral mechanism of deferent frequency TEAS pretreatment.

Detailed description

Patients were randomly assigned to three groups, receiving TEAS 30min before anesthesia. The frequency of high frequency group is set to 10/50HZ, low frequency group is 2/10HZ, and the fake stimulation group only attach electrodes without electric current. Acupoint selection is bilateral Neiguan points(PC6). Venous blood is collected 4ml before and immediately after TEAS respectively. Heart rate variability is monitored continuously during the 30min TEAS. The adverse events recorded.

Interventions

2/10HZ Electric stimulation was given through electrode attached to specific acupoints

DEVICEfake stimulation

Patients were only attached electrodes without electric current

Sponsors

wangqiang
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age 18yrs-65yrs * ASA 1-2 * Scheduled for elective operation under general anesthesia * BMI 18-30kg/m2 * Informed consented

Exclusion criteria

* Contraindications to TEAS * Communication difficulty with researchers * Addicted to alcohol, analgesics or other drugs * Cardiac insufficiency or high blood pressure without controlled * Hepatic or renal dysfunction * Participate in the other clinical trial 3 month before the enrollment

Design outcomes

Primary

MeasureTime frame
Plasma concentration of epinephrine(ng/L)change of TEAS 0 and 30 minutes
Plasma concentration of norepinephrine(ng/L)change of TEAS 0 and 30 minutes

Secondary

MeasureTime frame
Heart rate variabilityDuring 30min TEAS
plasma concentration of renin(ng/L)change of TEAS 0 and 30 minutes
plasma concentration of aldosterone(ng/L)change of TEAS 0 and 30 minutes
plasma concentration of glucocorticoid(μg/L)change of TEAS 0 and 30 minutes
plasma concentration of β-endorphin(ng/L)change of TEAS 0 and 30 minutes

Contacts

Primary ContactQiang Wang
wangqiang@fmmu.edu.cn86-29-84775343

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026